Inhibition of p38 mitogen-activated protein kinase potentiates the apoptotic effect of berberine/tumor necrosis factor-related apoptosis-inducing ligand combination therapy

Oncology Letters

Volumn 10, Issue 3, 2015, Pages 1907-1911

  Refaat, Alaa ^a,c   Abdelhamed, Sherif ^a   Saiki, Ikuo ^a   Sakurai, Hiroaki ^b,c  

^a UNIVERSITY OF TOYAMA   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c Zewail City of Science and Technology   (Egypt)

Author keywords

Apoptosis; Berberine; Epidermal growth factor receptor; Mitogen activated protein kinase; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

BERBERINE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER SURVIVAL; CELL VIABILITY ASSAY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION;

EID: 84937468915     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3494     Document Type: Article

References (19)

1. Refaat A, Abdelhamed S, Yagita H, Inoue H, Yokoyama S, HayakawaY and SaikiI: Berberine enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast cancer. Oncol Lett6: 840-844, 2013.
2. Zhang Y, Li X, Zhang Q, Li J, Ju J, Du N, Liu X, ChenX, ChengF, YangL, etal: Berberine hydrochloride prevents postsurgery intestinal adhesion and inflammation in rats. J Pharmacol Exp Ther349: 417-426, 2014.
3. Sakurai H: Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 33: 522-530, 2012.
4. Keane MM, Ettenberg SA, Nau MM, Russell EK and LipkowitzS: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res59: 734-741, 1999.
5. Tolcher AW, Mita M, Meropol NJ, von Mehren M, PatnaikA, PadavicK, Hill M, Mays T, McCoy T, Fox NL, et al: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25: 1390-1395, 2007.
6. Dyer MJ, MacFarlane M and Cohen GM: Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol25: 4505-4506, 2007.
7. Abdelhamed S, Yokoyama S, Refaat A, Ogura K, YagitaH, AwaleS and Saiki I: Piperine enhances the efficacy of TRAIL-based therapy for triple-negative breast cancer cells. Anticancer Res34: 1893-1899, 2014.
8. Refaat A, Abd-Rabou A and Reda A: TRAIL combinations: The new 'trail' for cancer therapy (Review). Oncol Lett7: 1327-1332, 2014.
9. Xu L, Zhang Y, Liu J, Qu J, Hu X, Zhang F, Zheng H, Qu X and LiuY: TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells. Eur J Cancer48: 3288-3299, 2012.
10. Xu L, Qu X, Li H, Li C, Liu J, ZhengH and LiuY: Src/caveolin-1-regulated EGFR activation antagonizes TRAIL-induced apoptosis in gastric cancer cells. Oncol Rep32: 318-324, 2014.
11. Choo MK, Kawasaki N, Singhirunnusorn P, Koizumi K, SatoS, AkiraS, SaikiI and SakuraiH: Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol Cancer Ther5: 2970-2976, 2006.
12. Nishimura M, Shin MS, Singhirunnusorn P, SuzukiS, KawanishiM, KoizumiK, SaikiI and SakuraiH: TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling. Mol Cell Biol29: 5529-5539, 2009.
13. Wang C, Chen T, Zhang N, Yang M, Li B, Lü X, CaoX and LingC: Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkappaB. J Biol Chem284: 3804-3813, 2009.
14. RefaatA, Aminullah, Zhou Y, Kawanishi M, TomaruR, AbdelhamedS, Shin MS, Koizumi K, Yokoyama S, SaikiI and SakuraiH: Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells. Biochem Biophys Res Commun458: 856-861, 2015.
15. Tong J, Taylor P, Peterman SM, Prakash A and MoranMF: Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041. Mol Cell Proteomics8: 2131-2144, 2009.
16. Refaat A, Zhou Y, Suzuki S, Takasaki I, Koizumi K, YamaokaS, TabuchiY, Saiki I and Sakurai H: Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9. J Biol Chem 286: 21092-21099, 2011.
17. Lee SJ, Noh HJ, Sung EG, Song IH, Kim JY, KwonTK and LeeTJ: Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins. Int J Oncol 38: 485-492, 2011.
18. Zaidi SF, Refaat A, Zhou Y, Sualeh Muhammad J, Shin MS, Saiki I, Sakurai H and Sugiyama T: Helicobacter pylori induces serine phosphorylation of EGFR via novel TAK1-p38 activation pathway in an HB-EGF-independent manner. Helicobacter: Feb23, 2015 (Epub ahead of print).
19. Zhou Y, Tanaka T, Sugiyama N, Yokoyama S, KawasakiY, SakumaT, IshihamaY, Saiki I and Sakurai H: p38-Mediated phosphorylation of Eps15 endocytic adaptor protein. FEBS Lett588: 131-137, 2014.